In October 2024, Dyno and Roche announced a second collaboration agreement, providing Roche further access to Dyno's advanced platform for neurological disease treatments.

Dyno’s LEAP technology enhances gene therapy vector engineering by generating high-performance capsid proteins.

This licensing agreement marks the conclusion of the initial collaboration between Dyno and Roche, which began in May 2020.

The original collaboration focused on developing next-generation AAV gene therapy vectors for central nervous system diseases and liver-directed therapies.

Dyno Therapeutics aims to overcome in vivo gene delivery challenges through AI and high-throughput experimentation, partnering with leading gene therapy developers.

Dyno applies artificial intelligence to optimize gene delivery, creating synthetic AAV capsids that outperform naturally occurring ones.

This AI-driven platform addresses key challenges in gene delivery by creating synthetic AAV capsids with optimized properties.

Dyno Therapeutics has announced that Roche has exercised its option to license a novel capsid for a gene therapy program targeting an undisclosed neurological disease.

As a result of this option exercise, Dyno will receive a $7 million payment and could potentially earn over $220 million in milestone payments and royalties.

Eric Kelsic, CEO of Dyno, highlighted this licensing agreement as a significant advancement for AI in gene therapy, validating the effectiveness of Dyno’s technology.

The capsid license is part of the collaboration agreement originally established in May 2020 between Dyno and Roche.

The exercise of the license option signifies a pivotal moment in the ongoing partnership between Dyno and Roche.